5. Conclusion
Our meta-analysis addressed the problems of previous meta-analyses and
also included more studies. The OS, DFS, and DSS did not differ
significantly between early stage OSCC patients without clinical neck
metastases undergoing SNB and END. SNB, which has no life-threatening
side effects, is preferable to END for patients with early stage
clinically node-negative OSCC.